세계 척추 성형술(Vertebroplasty and Kyphoplasty) 시장은 2023년 12억 달러에 달했고, 2031년에는 17억 달러에 달할 것으로 예상되며, 2024-2031년의 예측 기간 동안 5%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.
척추 성형술(Vertebroplasty 및 Kyphoplasty)은 척추압박골절로 인한 통증 치료를 위한 비교적 새로운 기술로, 척추를 안정화시켜 척추 기능장애의 확대를 막고 삶의 질을 향상시키는데 도움을 줍니다.
전만성형술은 척추체성형술과 달리 먼저 척추체 내에 풍선을 부풀려 공동을 만들고, 그 안에 시멘트를 저압으로 주입하는 수술입니다. 전만증은 골다공증, 암, 기타 질환으로 인한 척추압박골절을 안정화시키기 위해 사용되는 최신 척추 수술법입니다.
이 시장은 저침습 수술의 채택 증가, 골다공증 및 척추 질환 발병률 증가, 노인 인구 증가, 사고 사례 증가, 의료 기술 발전 등의 요인에 의해 주도되고 있습니다.
성장 촉진요인
골다공증 및 척추 질환 발생률 증가
세계 척추 성형술(Vertebroplasty and Kyphoplasty) 시장 수요는 여러 요인에 의해 주도되고 있습니다. 골다공증은 미국에서 널리 퍼져있는 공중 보건 문제입니다. 미국 외과 의사는 최근 골다공증의 중요성에 대해 미국인들에게 특별한 주의를 환기시켰습니다. 광범위한 조사에 따르면 척추 압박 골절은 골다공증의 가장 흔한 합병증 중 하나입니다.
백인 여성의 골다공증성 척추 골절의 평생 위험은 15.6%입니다. 미국에서는 매년 70만 건 이상의 골다공증에 따른 척추 골절이 진단되어 11만 5,000건의 입원이 발생합니다. 골다공증성 압박골절의 주요 결과는 허리 통증, 후만증, 키가 작아지는 것입니다.
또한, 이 업계의 주요 기업들이 신제품과 신기술을 발표하는 것은 이 시장의 성장을 가속할 것으로 보입니다. 예를 들어, 2023년 10월 네덜란드에 본사를 두고 척추 손상을 위한 차세대 임플란트를 개발하고 있는 앰버임플란트(Amber Implant)는 VCFix 척추 시스템의 임상시험을 시작했습니다. 이 임플란트는 페디클 앵커리지(pedicle anchorage)를 통해 척추의 하중 분산을 최적화하는 것을 목표로 하고 있습니다.
인간을 대상으로 한 첫 임상시험을 통해 척추 압박골절 환자를 대상으로 VCFix의 안전성과 유효성을 평가할 예정입니다. 또한 추적성을 보장하고 감염 위험을 줄이기 위해 일회용 멸균 수술 키트가 함께 제공됩니다.
또한, IZI Medical은 2021년 8월, 척추 성형술(Vertebroplasty 및 Kyphoplasty)에서 시멘트 주입 시 시멘트 주입 시 실시간 흐름의 가시화 요구에 대응하기 위한 제품인 Vertefix HV 시멘트를 정식으로 출시하였습니다.
억제요인
치료에 따른 높은 비용, 엄격한 규제 프레임워크, 시술에 따른 합병증, 숙련된 전문가 부족, 제한된 상환 정책 등의 요인이 시장을 저해할 것으로 예상됩니다.
Overview
The global vertebroplasty and kyphoplasty market reached US$ 1.2 billion in 2023 and is expected to reach US$ 1.7 billion by 2031, growing at a CAGR of 5% during the forecast period 2024-2031.
Vertebroplasty and kyphoplasty are relatively new techniques for the treatment of pain caused by vertebral body compression fractures and stabilize the spine, thereby preventing further spinal dysfunction and improving quality of life.
Kyphoplasty differs from vertebroplasty in that a balloon is first inflated in the vertebral body to create a cavity into which cement is then injected under lower pressure. Kyphosis is a modern spine surgery procedure used to stabilize vertebral compression fractures caused by osteoporosis, cancer, and other conditions.
The market is driven by factors such as a rise in the adoption of minimally invasive surgeries, a rising incidence of osteoporosis & spinal disorders, an increase in the geriatric population, a rise in accidental cases, and technological advancements in healthcare.
Market Dynamics
Drivers
Rising Incidence of Osteoporosis & Spinal Disorders
The demand for the global vertebroplasty and kyphoplasty market is driven by multiple factors. Osteoporosis is a widespread public health problem in the United States. The surgeon general of the United States has recently introduced special attention to the importance of osteoporosis to Americans extensive study states that vertebral body compression fractures are among the most common complications of osteoporosis.
The lifetime risk of osteoporotic spine fracture in white women is 15.6%. Each year, more than 700,000 vertebral body fractures secondary to osteoporosis are diagnosed in the United States, resulting in 115,000 hospital admissions. The major consequences of osteoporotic compression fractures are back pain, kyphosis, and height loss.
Moreover, major key players in the industry launching new products and technology would propel this market growth. For instance, in October 2023, Amber Implants, a Netherlands-based company developing next-gen implants for spinal injuries, began clinical trials for its VCFix spinal system. The implant seeks to optimize load distribution in the spine via pedicle anchorage.
The first-in-human trial will evaluate VCFix's safety and efficacy for patients with vertebral compression fractures. It's also included with a single-use, sterile surgical kit to ensure traceability and reduce infection risk.
Also, in August 2021, IZI Medical officially launched Vertefix HV Cement, a product which aims to address the need for real-time flow visualization during cement injection for vertebroplasty and kyphoplasty procedures.
Restraints
Factors such as the high cost associated with the treatment, stringent regulatory framework, complications associated with the procedures, lack of skilled professionals, and limited reimbursement policies are expected to hamper the market.
For more details on this report - Request for Sample
The global vertebroplasty and kyphoplasty market is segmented based on device type, application, end-user, and region.
The kyphoplasty device segment accounted for approximately 62.5% of the global vertebroplasty and kyphoplasty market share
The kyphoplasty segment is expected to hold the largest market share over the forecast period owing to the advantages that kyphoplasty provides over vertebroplasty, such as reduction in back pain, as well as restoration of vertebral body height, and a lower rate of cement extravasation. This is mainly done by placing balloons to gently elevate the fractured vertebrae in an attempt to return them to the correct position.
According to the study published in Frontiers in Surgery Journal in July 2022, the use of kyphoplasty for the clinical treatment of osteoporotic vertebral compression fractures, spinal metastatic tumors, hemangiomas, myelomas, and vertebral nonunion has increased with the global development of minimally invasive spinal surgery.
Therefore, the rising adoption of kyphoplasty procedures for the treatment of vertebral compression fractures and cancers will lead to increased adoption of kyphoplasty devices, expected to drive the segment's growth.
North America accounted for approximately 42.3% of the global vertebroplasty and kyphoplasty market share
North America region is expected to hold the largest market share over the forecast period owing to factors such as better healthcare infrastructure, rising funding from the government, awareness among people and healthcare industry stakeholders about available technologies, and the high concentration of market players in the region.
For instance, in September 2022, RevBio was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health. With the help of this grant, the company will be able to develop Tetranite, a patented bone adhesive technology, for the treatment of vertebral compression fractures.
Therefore, such funding for the development of technologies in vertebral compression fractures is expected to drive market growth due to the increased launch and adoption of products in the market over the forecast period.
Furthermore, according to Osteoporosis Canada, 2022, more than 2.3 million Canadians are living with osteoporosis and at least 1 in 3 women and 1 in 5 men suffer from an osteoporotic fracture during their lifetime. Such a huge prevalence of osteoporosis in Canada is expected to increase the adoption of vertebroplasty and kyphoplasty procedures in the Canadian population, thereby leading to the rising adoption of vertebroplasty and kyphoplasty devices, driving the market growth.
The COVID-19 pandemic significantly impacted the global vertebroplasty and kyphoplasty market. Hospital admissions for patients other than COVID-19 and serious diseases were restricted to hospitals to avoid the spread of the virus.
For instance, according to the study published in SAGE Journals in April 2022, there have been noticeable changes in the hospital admissions of patients with vertebral compression fractures (VCF) compared to the period before the COVID-19 pandemic. Fewer patients visited the emergency department for VCF during the peak of the Covid-19 pandemic which represented a 44% decrease. Hence, COVID-19 affected the pace of the market at the beginning of the pandemic.
The major global players in the vertebroplasty and kyphoplasty market include Medtronic, Jayon Implants, Johnson & Johnson, Joimax, Teknimed, Globus Medical, Stryker, MEDAID Inc, Biopsybell, and Merit Medical Systems among others.
The global vertebroplasty and kyphoplasty market report would provide approximately 62 tables, 55 figures, and 182 Pages.
Target Audience 2024
LIST NOT EXHAUSTIVE